SYM FINANCIAL Corp Invests $140,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

SYM FINANCIAL Corp acquired a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,586 shares of the company’s stock, valued at approximately $140,000.

A number of other large investors have also added to or reduced their stakes in TAK. FMR LLC grew its holdings in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after buying an additional 286,052 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares during the last quarter. Summit Global Investments raised its stake in shares of Takeda Pharmaceutical by 86.0% in the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock worth $5,909,000 after purchasing an additional 192,143 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after purchasing an additional 155,795 shares in the last quarter. Finally, Van ECK Associates Corp boosted its position in shares of Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after buying an additional 134,407 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK opened at $13.41 on Monday. The company’s 50-day simple moving average is $13.31 and its two-hundred day simple moving average is $13.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The stock has a market capitalization of $42.65 billion, a P/E ratio of 23.11, a P/E/G ratio of 0.25 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. As a group, analysts predict that Takeda Pharmaceutical Company Limited will post 1.55 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.